Cargando…
The Influence of Chimeric Antigen Receptor Structural Domains on Clinical Outcomes and Associated Toxicities
SIMPLE SUMMARY: The development and refinement chimeric antigen receptor (CAR)-T cell immunotherapy has significantly improved the prognosis of patients with B cell malignancies. Severe treatment related toxicities however remain a significant challenge for the field. This perspective reviews 17 cli...
Autores principales: | Davey, Ashleigh S., Call, Matthew E., Call, Melissa J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7794933/ https://www.ncbi.nlm.nih.gov/pubmed/33375550 http://dx.doi.org/10.3390/cancers13010038 |
Ejemplares similares
-
Chimeric antigen receptor modified T-cells for cancer treatment
por: Han, Xiao, et al.
Publicado: (2018) -
Chimeric antigen T cell receptor treatment in hematological malignancies
por: Ali, Natasha
Publicado: (2019) -
The FDA’s Regulatory Framework for Chimeric Antigen Receptor‐T Cell Therapies
por: Marks, Peter
Publicado: (2019) -
MicroRNA‐mediated metabolic reprogramming of chimeric antigen receptor T cells
por: Rad, Seyed Mohammad Ali Hosseini, et al.
Publicado: (2022) -
Chimeric Antigen Receptor T‐Cells: Successful Translation of the First Cell and Gene Therapy From Bench to Bedside
por: Rodriguez‐Cartagena, Luis G., et al.
Publicado: (2018)